Faron Pharmaceuticals Oy, a clinical stage biopharmaceutical company focused on precision immunotherapy for difficult-to-treat cancers and inflammation, has announced its financial calendar for 2024. On February 29, the company will release its financial statement for the full year 2023 and Annual Report 2023, including financial statements for the full year. On August 27, Faron will release its half-year financial report for the period January 1 to June 30, 2024. The annual general meeting is scheduled to be held on March 22, 2024. Faron's Board of Directors will issue a separate stock exchange notice to convene the meeting.

For more information, investors can contact LifeSci Advisors, ICR Consilium, Cairn Financial Advisers LLP, Peel Hunt LLP, or Sisu Partners Oy. Faron Pharmaceuticals Oy is a clinical stage biopharmaceutical company focused on precision immunotherapy for difficult-to-treat cancers and inflammation.